ClinicalTrials.gg
CompletedNCT06603220Updated May 19, 2026Results posted

A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria

A Phase 2 interventional study of Oral EVO756 300 mg QD and Oral EVO756 50 mg BID in Chronic Inducible Urticaria, sponsored by Evommune, Inc.. Completed at 18 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-19.

Sponsored by Evommune, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This phase 2a trial will evaluate the safety and efficacy of EVO756 in subjects with chronic inducible urticaria, including symptomatic dermographism and cold urticaria.

02

Conditions studied

  • Chronic Inducible Urticaria

Keywords

  • chronic inducible urticaria
  • inducible urticaria
03

In context

Lead sponsor

Evommune, Inc. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of chronic inducible urticaria for at least 3 months.
  • Positive response following provocation using the TempTest or FricTest at Screening and Day 1.

Exclusion criteria

Exclusion Criteria:

  • History of diseases other than chronic inducible urticaria or chronic spontaneous urticaria with urticaria or angioedema symptoms, such as urticarial vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria pigmentosa), and hereditary or acquired angioedema.
  • Concurrent use of certain medications, including antihistamines.
  • Any disease, or other skin disease or skin markings (e.g., extensive scarring, tattoos), that might confound the evaluation of safety or efficacy.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    EVO756 300 mg QD

    Oral EVO756 300 mg QD

    Drug: Oral EVO756 300 mg QD

  • Experimental
    EVO756 50 mg BID

    Oral EVO756 50 mg BID

    Drug: Oral EVO756 50 mg BID

Interventions

  • DrugOral EVO756 300 mg QD

    Oral EVO756, 300 mg once daily

  • DrugOral EVO756 50 mg BID

    Oral EVO756 50 mg twice daily

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability

    Safety will be assessed by the total number of subjects with at least one TEAE

    Time frame: Day 1 to Week 6

Secondary outcomes

  1. Change in Total Fric Score (TFS)

    The Total Fric Score represents the total number of linear wheals with a width of ≥3 mm induced following the Fric Test, from 0 to 4; 0 representing the minimum score (better outcome), and 4 representing the maximum score (worse outcome). A complete response is equal to a response of 0, where a subject began with at least a score of 1. A partial response is equal to a decrease of at least 2 points in the score (wheals), where a subject began with at least a score of 2. Partial responders may also be considered complete responders if their final score is equal to 0.

    Time frame: Day 1 to Week 4

  2. Change in Pruritus Severity at the Provocation Test Site

    The Pruritus Severity is determined based on the Pruritus Numeric Rating Scale, or P-NRS. This is an 11-point scale completed by the subject prior to and approximately 10 minutes after completion of the provocation test, where 10 represents the worst itch (maximum), and 0 represents no itch (minimum) at the site of the urticaria provocation test.

    Time frame: Day 1 to Week 4

07

Results

Posted May 19, 2026

Participant flow

Participant flow — Overall Study
MilestoneEVO756 300 mg QDEVO756 50 mg BID
Started1119
Completed1018
Not completed11
Withdrew: Withdrawal by subject10
Withdrew: Lost to follow-up01

Outcome measures

PrimarySafety and Tolerability

Safety will be assessed by the total number of subjects with at least one TEAE

Time frame:
Day 1 to Week 6
Reported as:
Number · Participants with a TEAE
Safety and Tolerability
Participants with a TEAEEVO756 300 mg QDEVO756 50 mg BID
Safety and Tolerability37
SecondaryChange in Total Fric Score (TFS)

The Total Fric Score represents the total number of linear wheals with a width of ≥3 mm induced following the Fric Test, from 0 to 4; 0 representing the minimum score (better outcome), and 4 representing the maximum score (worse outcome). A complete response is equal to a response of 0, where a subject began with at least a score of 1. A partial response is equal to a decrease of at least 2 points in the score (wheals), where a subject began with at least a score of 2. Partial responders may also be considered complete responders if their final score is equal to 0.

Time frame:
Day 1 to Week 4
Reported as:
Mean · Total Fric Score
Change in Total Fric Score (TFS)
Total Fric ScoreEVO756 300 mg QDEVO756 50 mg BID
Change in Total Fric Score (TFS)-1.4 ± 1.58-1.5 ± 1.33
SecondaryChange in Pruritus Severity at the Provocation Test Site

The Pruritus Severity is determined based on the Pruritus Numeric Rating Scale, or P-NRS. This is an 11-point scale completed by the subject prior to and approximately 10 minutes after completion of the provocation test, where 10 represents the worst itch (maximum), and 0 represents no itch (minimum) at the site of the urticaria provocation test.

Time frame:
Day 1 to Week 4
Reported as:
Mean · scores on a scale
Change in Pruritus Severity at the Provocation Test Site
scores on a scaleEVO756 300 mg QDEVO756 50 mg BID
Change in Pruritus Severity at the Provocation Test Site-2.4 ± 2.17-2.1 ± 2.77

Adverse events

Collected over 6 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
EVO756 300 mg QD0/11 (0%)0/11 (0%)3/11 (27.3%)
EVO756 50 mg BID0/19 (0%)0/19 (0%)7/19 (36.8%)
Most frequent other events
Showing 10 of 20
Most frequent other events
EventEVO756 300 mg QDEVO756 50 mg BID
Alanine Aminotransferase IncreasedInvestigations2/110/19
Aspartate Aminotransferase IncreasedInvestigations2/110/19
FatigueGeneral disorders1/110/19
Hepatic CystHepatobiliary disorders1/110/19
GastroenteritisInfections and infestations1/111/19
Viral Upper Respiratory Tract InfectionInfections and infestations1/110/19
Vulvovaginal Mycotic InfectionInfections and infestations1/110/19
Back PainMusculoskeletal and connective tissue disorders1/110/19
SciaticaNervous system disorders1/110/19
Renal CystRenal and urinary disorders1/110/19

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)EVO756 300 mg QDEVO756 50 mg BIDTotal
<=18 years000
Between 18 and 65 years111930
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)EVO756 300 mg QDEVO756 50 mg BIDTotal
Female71724
Male426
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)EVO756 300 mg QDEVO756 50 mg BIDTotal
Hispanic or Latino156
Not Hispanic or Latino101424
Unknown or Not Reported000
08

Study locations

18 sites
  • Cahaba Dermatology & Skin Health Center, LLC
    Birmingham, Alabama 35244, United States
  • California Allergy and Asthma Medical Group
    Los Angeles, California 90025, United States
  • Integrative Skin Science and Research
    Sacramento, California 95815, United States
  • West Dermatology Research Center
    San Diego, California 92121, United States
  • Advanced Clinical Research Institute
    Tampa, Florida 33607, United States
  • Aeroallergy Research Laboratories of Savannah, Inc.
    Savannah, Georgia 31406, United States
  • Treasure Valley Medical Research
    Boise, Idaho 83706, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46250, United States
  • Southern Indiana Clinical Trials
    New Albany, Indiana 47150, United States
  • Indiana Clinical Trials Center, P.C.
    Plainfield, Indiana 46168, United States
  • DelRicht Research
    Baton Rouge, Louisiana 70809, United States
  • Chesapeake Clinical Research, Inc
    White Marsh, Maryland 21162, United States
  • OptiSkin Medical
    New York, New York 10128, United States
  • Red River Research Partners
    Fargo, North Dakota 58013, United States
  • Bexley Dermatology Research
    Bexley, Ohio 43209, United States
  • Allergy, Asthma, and Clinical Research Center
    Oklahoma City, Oklahoma 73120, United States
  • Allergy and Clinical Immunology Associates
    Pittsburgh, Pennsylvania 15241, United States
  • Austin Institute for Clinical Research
    Pflugerville, Texas 78660, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2024 to primary completion in May 2025, 8 months.

Results were first posted in May 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2024
First posted
Sep 19, 2024
StartActual
Aug 14, 2024
Primary completionActual
May 8, 2025
CompletionActual
May 8, 2025
Results first posted
May 19, 2026
Last update
May 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06603220
Lead sponsor
Evommune, Inc.
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Aug 14, 2024
Primary completion
May 8, 2025
Completion
May 8, 2025
Results posted
May 19, 2026
Last update
May 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion